From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:2oz7.jpg|left|200px]] | + | {{Seed}} |
| | + | [[Image:2oz7.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_2oz7| PDB=2oz7 | SCENE= }} | | {{STRUCTURE_2oz7| PDB=2oz7 | SCENE= }} |
| | | | |
| - | '''Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate'''
| + | ===Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | Cyproterone acetate (CPA) is a steroidal antiandrogen used clinically in the treatment of prostate cancer. Compared with steroidal agonists for the androgen receptor (AR) (e.g. dihydrotestosterone, R1881), CPA is bulkier in structure and therefore seemingly incompatible with the binding pockets observed in currently available x-ray crystal structures of the AR ligand-binding domain (LBD). We solved the x-ray crystal structure of the human AR LBD bound to CPA at 1.8A in the T877A variant, a mutation known to increase the agonist activity of CPA and therefore facilitate purification and crystal formation of the receptor.drug complex. The structure demonstrates that bulk from the 17alpha-acetate group of CPA induces movement of the Leu-701 side chain, which results in partial unfolding of the C-terminal end of helix 11 and displacement of the loop between helices 11 and 12 in comparison to all other AR LBD crystal structures published to date. This structural alteration leads to an expansion of the AR binding cavity to include an additional pocket bordered by Leu-701, Leu-704, Ser-778, Met-780, Phe-876, and Leu-880. Further, we found that CPA invokes transcriptional activation in the L701A AR at low nanomolar concentrations similar to the T877A mutant. Analogous mutations in the glucocorticoid receptor (GR) and progesterone receptor were constructed, and we found that CPA was also converted into a potent agonist in the M560A GR. Altogether, these data offer information for structure-based drug design, elucidate flexible regions of the AR LBD, and provide insight as to how CPA antagonizes the AR and GR.
| + | The line below this paragraph, {{ABSTRACT_PUBMED_17311914}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 17311914 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_17311914}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 30: |
Line 34: |
| | [[Category: Anti-androgen]] | | [[Category: Anti-androgen]] |
| | [[Category: Prostate cancer]] | | [[Category: Prostate cancer]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 11:58:33 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 21:01:28 2008'' |
Revision as of 18:01, 27 July 2008
Template:STRUCTURE 2oz7
Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate
Template:ABSTRACT PUBMED 17311914
About this Structure
2OZ7 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design., Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT, J Biol Chem. 2007 May 4;282(18):13648-55. Epub 2007 Feb 20. PMID:17311914
Page seeded by OCA on Sun Jul 27 21:01:28 2008
